Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15326898 | 0.76 | KEAP1 (0.43) | KEAP1MEN1KMT2ASIGMAR1ADRA2C | |
| SCHEMBL4427808 | 0.75 | ADRA2C (0.53) | KEAP1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL7819847 | 0.72 | SIGMAR1 (0.50) | KEAP1MEN1KMT2ASIGMAR1NPC1 | |
| SCHEMBL4427099 | 0.71 | MAPK1 (0.54) | KEAP1SIGMAR1RAB9AADRA2CALDH1A1 | |
| SCHEMBL11326554 | 0.71 | MAPK1 (0.54) | KEAP1SIGMAR1RAB9AADRA2CALDH1A1 | |
| SCHEMBL9607913 | 0.71 | SIGMAR1 (0.48) | MEN1KMT2ASIGMAR1NPC1RAB9A | |
| SCHEMBL16786521 | 0.70 | DDB1 (0.52) | MEN1KMT2AALDH1A1ADRB1 | |
| SCHEMBL30261935 | 0.69 | SIGMAR1 (0.48) | MEN1KMT2ASIGMAR1NPC1RAB9A | |
| SCHEMBL12153468 | 0.69 | SIGMAR1 (0.48) | MEN1KMT2ASIGMAR1NPC1RAB9A | |
| SCHEMBL15326871 | 0.68 | NPC1 (0.51) | MEN1KMT2ANPC1RAB9AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150554-B2 | Fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-8999967-B2 | Tricyclic fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2012052104-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012050918-A2 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICAL, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-7879221-B2 | oxidation of anode comprising metal corresponding to metal ion in reaction medium in the presence of organic compound which is optionally substituted mono, bi, or polycyclic hydrocarbon in which two ring carbons have been replaced by N,O, or S, reaction of product with di, tri, or tetracarboxylic acid | BASF SE (DE) | 2011-02-01 | — | — | US | disclosed |
| US-7879221-B2 | oxidation of anode comprising metal corresponding to metal ion in reaction medium in the presence of organic compound which is optionally substituted mono, bi, or polycyclic hydrocarbon in which two ring carbons have been replaced by N,O, or S, reaction of product with di, tri, or tetracarboxylic acid | BASF SE (DE) | 2011-02-01 | — | — | US | disclosed |
| WO-2010111534-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| EP-2049550-B1 | METHOD FOR PRODUCING COPPER-CONTAINING ORGANOMETALLIC FRAMEWORK MATERIAL | BASF SE (DE) | 2010-01-06 | — | — | EP | disclosed |
| US-20090306420-A1 | PROCESS FOR PREPARING COPPER-COMPRISING METAL ORGANIC FRAMEWORKS | BASF SE (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306420-A1 | PROCESS FOR PREPARING COPPER-COMPRISING METAL ORGANIC FRAMEWORKS | BASF SE (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-2027307-B1 | PROCESS FOR PREPARING POROUS METAL ORGANIC FRAMEWORKS | BASF SE (DE) | 2009-11-04 | — | — | EP | disclosed |
| US-20090171107-A1 | PROCESS FOR PREPARING POROUS METAL ORGANIC FRAMEWORKS | BASF SE (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20090171107-A1 | PROCESS FOR PREPARING POROUS METAL ORGANIC FRAMEWORKS | BASF SE (DE) | 2009-07-02 | — | — | US | disclosed |
| WO-2008012216-A1 | METHOD FOR PRODUCING COPPER-CONTAINING ORGANOMETALLIC FRAMEWORK MATERIAL | BASF SE (DE) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007131948-A2 | PROCESS FOR PREPARING POROUS METAL ORGANIC FRAMEWORKS | BASF SE (DE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | HAVCR2, HCCS, LIPC | KEAP1 345/4885MEN1 4857/4885KMT2A 4238/4885 |
| US-20090171107-A1 | PROCESS FOR PREPARING POROUS METAL ORGANIC FRAMEWORKS | OSTC, OGDH, SCO2 | KEAP1 2843/4885MEN1 2489/4885KMT2A 2798/4885 |
| US-20090306420-A1 | PROCESS FOR PREPARING COPPER-COMPRISING METAL ORGANIC FRAMEWORKS | AOC1, AOC2, AOC3 | KEAP1 207/4885MEN1 975/4885KMT2A 2523/4885 |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | HAVCR2, HCCS, ZC3HAV1 | KEAP1 194/4885MEN1 4843/4885KMT2A 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.